Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has earned a consensus rating of "Moderate Buy" from the thirteen ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $88.77.

RARE has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. William Blair initiated coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price target for the company. Piper Sandler reduced their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Monday, March 17th. Canaccord Genuity Group increased their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $37.17 on Friday. The company has a market cap of $3.51 billion, a PE ratio of -5.86 and a beta of 0.25. Ultragenyx Pharmaceutical has a 52-week low of $29.59 and a 52-week high of $60.37. The stock has a 50-day simple moving average of $35.58 and a 200 day simple moving average of $40.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The firm had revenue of $139.29 million for the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm's quarterly revenue was up 28.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.03) earnings per share. On average, research analysts predict that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC increased its stake in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 493 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth $35,000. Human Investing LLC bought a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth $42,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth $57,000. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.